Keywords: Roche, Avastin, Breast cancer, USA, FDA, Lucentis, DME, Diabetic macular edema

US FDA advisory panel nixes Roche’s Avastin for breast cancer; but good news on Lucentis in DME

Article | 30 June 2011

Print This

Genentech, the US subsidiary of Swiss drug major Roche (RGO: SIX), suffered a blow yesterday, when, after a two-day appeal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in